CO6241127A2 - Composicion de portador de suministro de acido nucleico - Google Patents
Composicion de portador de suministro de acido nucleicoInfo
- Publication number
- CO6241127A2 CO6241127A2 CO09120191A CO09120191A CO6241127A2 CO 6241127 A2 CO6241127 A2 CO 6241127A2 CO 09120191 A CO09120191 A CO 09120191A CO 09120191 A CO09120191 A CO 09120191A CO 6241127 A2 CO6241127 A2 CO 6241127A2
- Authority
- CO
- Colombia
- Prior art keywords
- nucleic acid
- component
- acid delivery
- carrier
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
Un objeto de la presente invención es para proporcionar una composición de portador para suministro de ácido nucleico, que puede suministrar eficientemente un ácido nucleico en las células cuando un ácido nucleico tal como se administra siARN a células derivadas de anima! o animales, y también tiene baja toxicidad y alta seguridad, y una composición para suministro de ácido nucleico que contiene la composición de portador y ácido nucleico. Se prepara un portador para suministro de ácido nucleico al utilizar (A) una diacilfosfatidilcolina, (B) por lo menos un miembro seleccionado del grupo que consiste de colesterol y derivados del mismo, y (C) una amina primaria alifática. También, una composición para suministro de ácido nucleico se prepara al mezclar el portador para suministro de ácido nucleico con un ácido nucleico. 1.- Una composición de portador para suministro de ácido nucleico, que comprende (A) una diacilfosfatidilcolina, (B) por lo menos un miembro seleccionado del grupo que consiste de colesterol y derivados del mismo, y (C) una amina primaria alifática. 2.- La composición de portador para suministro de ácido nucleico de acuerdo con la Reivindicación 1, en donde el componente (A) es una diacilfosfatidilcolina cuyo grupo funcional acilo tiene 4 a 23 átomos de carbono. 3.- La composición de portador para suministro de ácido nucleico de acuerdo con la Reivindicación 1 o 2, en donde el componente (B) es colesterol. 4.- La composición de portador para suministro de ácido nucleico de acuerdo con la Reivindicación 1, en donde el componente (C) es una alquilamina que tiene 10 a 20 átomos de carbono. 5.- La composición de portador para suministro de ácido nucleico de acuerdo con la Reivindicación 1, en donde el componente (A) es por lo menos un miembro seleccionado del grupo que consiste de dimiristoilfosfatidilcolina, dipalmitoilfosfatidilcolina, y diestearoilfosfatidilcolina; el componente (B) es colesterol; y el componente (C) es estearilamina. 6.- La composición de portador para suministro de ácido nucleico de acuerdo con la Reivindicación 1, en donde la relación molar del componente (A): componente (B): componente (C) es 5-9:1-5:1. 7.- La composición de portador para suministro de ácido nucleico de acuerdo con la Reivindicación 1, que es un portador para suministro de siARN.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007079944 | 2007-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6241127A2 true CO6241127A2 (es) | 2011-01-20 |
Family
ID=39788561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09120191A CO6241127A2 (es) | 2007-03-26 | 2009-10-26 | Composicion de portador de suministro de acido nucleico |
Country Status (27)
Country | Link |
---|---|
US (1) | US9315828B2 (es) |
EP (1) | EP2140870B1 (es) |
JP (1) | JP5349293B2 (es) |
KR (1) | KR101459391B1 (es) |
CN (1) | CN101646443B (es) |
AR (1) | AR065847A1 (es) |
AU (1) | AU2008230379B2 (es) |
BR (1) | BRPI0809634A2 (es) |
CA (1) | CA2682490A1 (es) |
CO (1) | CO6241127A2 (es) |
DK (1) | DK2140870T3 (es) |
ES (1) | ES2542864T3 (es) |
HK (1) | HK1139041A1 (es) |
HR (1) | HRP20150927T1 (es) |
HU (1) | HUE027053T2 (es) |
IL (1) | IL201116A0 (es) |
MX (1) | MX2009010336A (es) |
MY (1) | MY151450A (es) |
NZ (1) | NZ579804A (es) |
PL (1) | PL2140870T3 (es) |
PT (1) | PT2140870E (es) |
RU (1) | RU2476229C2 (es) |
SI (1) | SI2140870T1 (es) |
TW (1) | TWI428135B (es) |
UA (1) | UA97143C2 (es) |
WO (1) | WO2008117828A1 (es) |
ZA (1) | ZA200906576B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110128325A (ko) | 2009-03-04 | 2011-11-29 | 히로후미 다케우치 | 핵산 복합체 및 핵산 송달용 조성물 |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
EP3144015B1 (en) | 2010-09-20 | 2021-06-02 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
JP6029131B2 (ja) * | 2011-12-28 | 2016-11-24 | 国立研究開発法人国立循環器病研究センター | 核酸導入剤、核酸導入方法及び細胞 |
EP3554546A4 (en) | 2016-12-14 | 2021-04-14 | Ligandal, Inc. | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF NUCLEIC ACID AND PROTEIN PAYLOADS |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2184834A1 (en) | 1994-03-11 | 1995-09-14 | Yoshiyuki Mori | Liposome preparation |
US20030092180A1 (en) | 2001-08-27 | 2003-05-15 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
US6126964A (en) | 1996-01-04 | 2000-10-03 | Mirus Corporation | Process of making a compound by forming a polymer from a template drug |
US6358523B1 (en) * | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
US6835395B1 (en) * | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
JPH10313872A (ja) * | 1997-05-21 | 1998-12-02 | Soyaku Gijutsu Kenkyusho:Kk | 抗インフルエンザウイルス剤 |
WO1999013816A2 (en) | 1997-09-16 | 1999-03-25 | Nexstar Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
US6740335B1 (en) | 1997-09-16 | 2004-05-25 | Osi Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
JPH11292795A (ja) * | 1998-04-02 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | Hivコファクター抑制剤 |
PT1129064E (pt) | 1998-11-12 | 2008-01-31 | Invitrogen Corp | Reagentes de transfecção |
CA2421409A1 (fr) * | 2000-09-08 | 2002-03-14 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
AU2003296897A1 (en) * | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
US20060030578A1 (en) | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
PL377161A1 (pl) * | 2002-11-21 | 2006-01-23 | Pevion Biotech Ltd. | Wysoce efektywne pęcherzyki fuzogenne, sposób ich wytwarzania oraz kompozycje farmaceutyczne zawierające te pęcherzyki |
US20040208921A1 (en) * | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
WO2005000796A1 (ja) * | 2003-06-27 | 2005-01-06 | Sumitomo Chemical Company, Limited | アミド化合物およびそれを用いた植物病害の防除方法 |
WO2005007196A2 (en) * | 2003-07-16 | 2005-01-27 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
WO2005027979A2 (en) * | 2003-09-17 | 2005-03-31 | Let There Be Hope Medical Research Institute | Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
EP1759691A1 (en) | 2003-11-20 | 2007-03-07 | Delex Therapeutics Inc. | Stable liposome compositions |
AT500143A1 (de) * | 2004-04-22 | 2005-11-15 | Sanochemia Pharmazeutika Ag | Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung |
JP2005336081A (ja) | 2004-05-26 | 2005-12-08 | Anges Mg Inc | Nr2b−nmda受容体の再発現抑制剤 |
US7807815B2 (en) | 2004-07-02 | 2010-10-05 | Protiva Biotherapeutics, Inc. | Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA |
EP2199298A1 (en) | 2004-11-17 | 2010-06-23 | Protiva Biotherapeutics Inc. | Sirna silencing of Apolipoprotein B |
WO2006138380A2 (en) * | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
WO2007048019A2 (en) * | 2005-10-20 | 2007-04-26 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
UA97559C2 (uk) | 2007-11-08 | 2012-02-27 | Оцука Фармасьютікал Ко., Лтд. | Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти |
-
2008
- 2008-03-25 TW TW097110544A patent/TWI428135B/zh not_active IP Right Cessation
- 2008-03-26 HU HUE08738918A patent/HUE027053T2/en unknown
- 2008-03-26 KR KR1020097021571A patent/KR101459391B1/ko not_active IP Right Cessation
- 2008-03-26 UA UAA200910735A patent/UA97143C2/ru unknown
- 2008-03-26 EP EP08738918.5A patent/EP2140870B1/en active Active
- 2008-03-26 AR ARP080101222A patent/AR065847A1/es unknown
- 2008-03-26 CN CN200880010035.6A patent/CN101646443B/zh not_active Expired - Fee Related
- 2008-03-26 NZ NZ579804A patent/NZ579804A/en not_active IP Right Cessation
- 2008-03-26 RU RU2009139246/15A patent/RU2476229C2/ru not_active IP Right Cessation
- 2008-03-26 WO PCT/JP2008/055730 patent/WO2008117828A1/ja active Application Filing
- 2008-03-26 DK DK08738918.5T patent/DK2140870T3/en active
- 2008-03-26 MX MX2009010336A patent/MX2009010336A/es active IP Right Grant
- 2008-03-26 BR BRPI0809634-1A2A patent/BRPI0809634A2/pt not_active IP Right Cessation
- 2008-03-26 AU AU2008230379A patent/AU2008230379B2/en not_active Ceased
- 2008-03-26 PL PL08738918T patent/PL2140870T3/pl unknown
- 2008-03-26 SI SI200831495T patent/SI2140870T1/sl unknown
- 2008-03-26 MY MYPI20093905 patent/MY151450A/en unknown
- 2008-03-26 PT PT87389185T patent/PT2140870E/pt unknown
- 2008-03-26 ES ES08738918.5T patent/ES2542864T3/es active Active
- 2008-03-26 CA CA002682490A patent/CA2682490A1/en not_active Abandoned
- 2008-03-26 US US12/532,949 patent/US9315828B2/en active Active
- 2008-03-26 JP JP2009506363A patent/JP5349293B2/ja active Active
-
2009
- 2009-09-21 ZA ZA2009/06576A patent/ZA200906576B/en unknown
- 2009-09-23 IL IL201116A patent/IL201116A0/en unknown
- 2009-10-26 CO CO09120191A patent/CO6241127A2/es active IP Right Grant
-
2010
- 2010-05-14 HK HK10104730.5A patent/HK1139041A1/xx not_active IP Right Cessation
-
2015
- 2015-09-03 HR HRP20150927TT patent/HRP20150927T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6241127A2 (es) | Composicion de portador de suministro de acido nucleico | |
CO6270324A2 (es) | Derivados de pirimidina para el tratamiento del asma epoc rinitis conjutivitis alergica dermatitis atopica cancer hepatitis b hepatitis c vih vph infecciones bacterianas y dermatosis | |
DOP2013000238A (es) | Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
UY38382A (es) | Agentes de arni para inhibir la expresión de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y métodos de uso | |
BR112017009601A2 (pt) | derivados de aminoácidos e seus usos | |
BR112015019590A2 (pt) | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv | |
BR112015004529A8 (pt) | alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende | |
ECSP11011470A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
CR11641A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211 | |
ECSP077404A (es) | Derivados de purina para usarse como agonistas de receptores a-2a de adenosina | |
IN2014DN03325A (es) | ||
BR112013024706A2 (pt) | análogos de exendina mono-peguilada em sítio específico e respectivo método de preparo | |
AR071533A1 (es) | Microemulsion mejorada con un amplio rango de aplicacion | |
AR084978A1 (es) | Metodo y composicion para suministrar ingrediente activo al aire y su uso | |
ECSP099425A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2 | |
CR11825A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
AR078736A1 (es) | Una solucion de droga de taxanos que comprende un regulador de ph y su metodo de preparacion | |
BR112022013599A2 (pt) | Nanomateriais | |
CO6280469A2 (es) | Complejo de acido nucleico y composicion de suministro de acidos nucleicos | |
MY149502A (en) | Carrier composition for nucleic acid transport | |
BR112015011611A2 (pt) | composição de revestimento e artigo revestido | |
BR112014013906A2 (pt) | ésteres de fosfato aromáticos como componentes de formulação agroquímica | |
GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon | |
ES2563243T3 (es) | Alcoxilatos de cocoalquilpoliamina como agentes para composiciones de herbicida de alta concentración | |
CL2008003045A1 (es) | Compuestos derivados de dioxolano timina fosforamidatos; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de infecciones virales, tales como el vih |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused | ||
FG | Application granted |